Literature DB >> 18187011

[Which tumor patients profit from interdisciplinary psychoeducation in the framework of a tumor therapy?].

Harald Gündel1, Verena Hümmeler, Florian Lordick.   

Abstract

OBJECTIVES: In the following study we investigate which patients gained most by attending 10 psychoeducational lessons on cancer-related topics.
METHODS: A total of N=294 cancer patients participated in the prospective study and were assigned either to the intervention group (IG; N=160) or to the control group (CG; N=134). Psychometric data was collected at the beginning of the course (t0) as well as two (t1) and four months later (t2)
RESULTS: We found a significant decrease in anxiety after two months in the intervention group. The intervention group also was significantly more satisfied with care after two and four months. Particularly the patients with a higher education level and patients suffering from malignancies with a more protracted course such as lymphoma or colon cancer improved by attending the lessons. Breast cancer and female sex turned out to be predictors for the search for information.
CONCLUSION: Ten sessions of psychoeducation in the context of interdisciplinary cancer therapy can be an effective intervention at moderate cost.

Entities:  

Mesh:

Year:  2007        PMID: 18187011

Source DB:  PubMed          Journal:  Z Psychosom Med Psychother        ISSN: 1438-3608            Impact factor:   0.791


  2 in total

1.  Routine psychosocial distress screening in radiotherapy: implementation and evaluation of a computerised procedure.

Authors:  A Dinkel; P Berg; C Pirker; H Geinitz; S Sehlen; M Emrich; B Marten-Mittag; G Henrich; K Book; P Herschbach
Journal:  Br J Cancer       Date:  2010-10-26       Impact factor: 7.640

2.  Documentation and Communication of Psychooncological Findings in an Interdisciplinary Breast Cancer Center.

Authors:  Anne Grimm; Barbara Voigt; Petra Georgiewa; Thomas Fydrich; Dieter Kleiber; Burghard F Klapp; Martina Rauchfuß
Journal:  Breast Care (Basel)       Date:  2009-10-01       Impact factor: 2.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.